US Patent 9827310 Anti-ErbB3 antibodies and uses thereof
Patent 9827310 was granted and assigned to Regeneron Pharmaceuticals on November, 2017 by the United States Patent and Trademark Office.
All edits
Edits on 6 Dec, 2023
Golden AI
Edits made to:
Article (+440 characters)
Article
Patent abstract
The present invention provides antibodies that bind to ErbB3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human ErbB3. In certain embodiments, the antibodies of the present invention block the interaction of ErbB3 with an ErbB3 ligand such as neuregulin 1. The antibodies of the invention are useful for the treatment of various cancers.
Edits on 4 Oct, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 1 Oct, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Christopher Daly0
Douglas MacDonald0
Xunbao Duan0
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09827310 Anti-ErbB3 antibodies and uses thereof US Patent 9827310 Anti-ErbB3 antibodies and uses thereof
Infobox
Patent Number
098273100
Patent Number
98273100
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
098273100
Date of Patent
November 28, 2017
0Patent Application Number
150119780
Date Filed
February 1, 2016
0Patent Primary Examiner
Edits on 15 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09827310 Anti-ErbB3 antibodies and uses thereof
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09827310
Date of patent
November 28, 2017
Patent application number
15011978
Date Filed
February 1, 2016
Patent primary examiner
Find more entities like US Patent 9827310 Anti-ErbB3 antibodies and uses thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
